Translational analysis of esophageal adenocarcinoma (EAC) patients treated with oxaliplatin and capecitabine (Xelox) +/- the dual ErbB inhibitor AZD8931 in the DEBIOC study
Main Authors: | Lavery, A, Stevenson, L, McManus, D, Logan, GE, Walker, SM, Jellema, GL, Van Schaeybroeck, S, Virdee, PS, Middleton, MR, Elhussein, L, Turbitt, J, Colinson, D, Miedzybrodzka, Z, Petty, RD, Harkin, PD, Kennedy, RD, Eatock, MM, Thomas, AL, Turkington, RC |
---|---|
Format: | Conference item |
Language: | English |
Published: |
American Society of Clinical Oncology
2020
|
Similar Items
-
A Phase I dose-finding and safety study of AZD8931 with Oxaliplatin and Capecitabine chemotherapy in patients with Oesophago-gastric adenocarcinoma: the randomised expansion phase of the DEBIOC trial
by: Thomas, A, et al.
Published: (2018) -
Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma
by: Thomas, A, et al.
Published: (2019) -
Accreditation visit engineering accreditation council (EAC)
by: 495834 Universiti teknologi Malaysia
Published: (2014) -
Trade with the EU, Variable Geometry and Human Rights in the EAC
by: Aleydis Nissen
Published: (2022-02-01) -
FOXO transcriptional activity is associated with response to chemoradiation in EAC
by: A. Creemers, et al.
Published: (2022-04-01)